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Clinical and Pathological Features of Young Idiopathic Membranous
Nephropathy
Juan Jin, Qiang He
Department of Nephrology, Zhejiang Province People’s Hospital, Hangzhou,
Zhejiang, China
Objective: To investigate the clinical and pathological features of idiopathic
membranous nephropathy (IMN) in young patients.
Methods: Clinical data about 20 patients who were diagnosed as IMN in
young patients admitted to the Zhejiang Provincial people’s Hospital from
January 2013 to December 2014 were retrospectively analyzed, comparing
to the 55 patients who were diagnosed with IMN as older patients during
the same period in hospital. Analysis of the clinical and pathological
features.
Results: The morbidity of IMN in young patients is rising (accounted or IMN
26.7%), and have low proportion of hypertension, hyperglycemia and scle-
rosis glomeruli than IMN in older patients (P Z 0.002; P Z 0.044; P <
0.0001). There were higher eGFR and LDL level than latter (P Z 0.027;
PZ 0.038) but with low levels of T3 and T4 (PZ 0.03; PZ 0.034). Further-
more, there was less hyaline change of arteriole and arteriolar wall thick-
ening than latter (P Z 0.027; P < 0.0001).
Conclusion: IMN in young patients have low proportion of hypertension, hyper-
glycemia and sclerosis glomeruli than IMN in older patients, and with higher
eGFR and LDL and lower levels of T3 and T4 than the latter. Furthermore, there
is less hyaline change in arteriole and arteriolar wall thickening than latter.http://dx.doi.org/10.1016/j.hkjn.2015.09.0170178
Soluble Urokinase-type Plasminogen Activator Receptor Serum Levels in
Adults with Nephrotic Syndrome
Fan Qiuling
Department of Nephropathy, The First Affiliated Hospital of China Medical
University, Shenyang, China
Objective: The serum levels of soluble urokinase type fibrinolytic enzyme ac-
tivators receptor (suPAR) in adults with nephrotic syndrome were analyzed.
Methods: The serum levels of soluble urokinase type fibrinolytic enzyme ac-
tivators receptor (suPAR) in 70 nephrotic syndrome patients with membra-
nous nephropathy, diabetic nephropathy group, lupus nephritis, minimal
change kidney disease and focal segmental glomerular sclerosis group was
detected by enzyme-linked immunosorbent assay. The relationship between
the the clinical parameters and suPAR levels were analyzed.
Results: Serum soluble urokinase receptor levels of nephrotic syndrome pa-
tients are significantly higher than the normal control group (P < 0.01). The
serum suPAR levels of FSGS and MN patients were significant higher than MCD
patients (P < 0.05). Serum suPAR level was positively correlated with age,
serum creatinine, blood urea nitrogen (rs Z 0.401, p Z 0.001; rs Z 0.286,
p Z 0.016; rs Z 0.249, p Z 0.037; rs Z 0.245, p Z 0.041; rs Z 0.247,
p Z 0.039), and negatively correlated with eGFR (rs Z 0.265,
p Z 0.026; rs Z 0.237, p Z 0.048; rs Z 0.309, p Z 0.009).
Conclusion: Serum suPAR level was positively correlated with age, serum
creatinine, blood urea nitrogen, and negatively correlated with eGFR. The
serum suPAR levels of FSGS and MN patients were significant higher than
MCD patients and may be a potential marker to distinguish FSGS and MCD.http://dx.doi.org/10.1016/j.hkjn.2015.09.0180183
Clinical Trial of Treatment for Idiopathic Membranous Nephropathy with
Leflunomide Combined with Cyclophosphamide and Glucocorticoid
Shuzhen Liu
AnYang City People Hospital, AnYang, Henan Province, China
Objective: To study the efficacy and safety of treating idiopathic membra-
nous nephropathy with leflunomide and cyclophosphamide andglucocorticoid, compared with traditional oral cyclophosphamide therapy
and leflunomide therapy.
Methods: Seventy-two patients were randomly divided into three groups:
Group A (glucocorticoid + cyclophosphamide, n Z 24), Group B (glucocorti-
coid + leflunomide, n Z 24), Group C (glucocorticoid + cyclophosphamide +
leflunomide, nZ 24). We observed the urine protein quantitative and other
clinical indexes and safety during follow-up.
Results: After all patients completed 1 year’s observation, the complete
remission rates in Group A, Group B and Group C were 58.3%, 62.5% and
87.5%, respectively. The urine protein quantitative was significantly
decreased compared with Group B and Group C, and their difference was
statistically significant (P < 0.05). Serum albumin and serum total choles-
terol were significantly improved compared to before treatment (P <
0.05). There was no significant difference in serum creatinine (P > 0.05).
Conclusion: In general, treatment of idiopathic membranous nephropathy
with leflunomide and cyclophosphamide and glucocorticoid is better than
with oral cyclophosphamide therapy and leflunomide therapy, with good
tolerance and no increase in adverse reactions.http://dx.doi.org/10.1016/j.hkjn.2015.09.0190185
Value of Plasma Growth Differentiation Factor-15 in Primary Nephrotic
Syndrome
Pengxiao Shen, Jiansheng Wang
Department of Nephrology, The Second Affiliated Hospital, Zhengzhou
University, Zhengzhou, China
Objective: To detect the plasma level of growth differentiation factor-15
(GDF-15) in patients with primary nephrotic syndrome and in healthy people,
then to assess its value in primary nephrotic syndrome.
Methods: Choose healthy adult volunteers as the healthy control group (group
A, n Z 60). Choose primary nephrotic syndrome patients as glucocorticoids
and tacrolimus treatment group (group B, nZ 60). Patients in glucocorticoids
and tacrolimus treatment group were given prednisone and tacrolimus. The
dose of prednisone was 0.1 mg/kg/d. The dose of tacrolimus was 0.1 mg/
kg/d, maintaining blood concentrations of 4e10 ng/ml, and gradually reduced
after 3 months. Before treatment (0 w), plasma albumin, liver and kidney
function, 24-hour urine protein quantitative, plasma concentrations of GDF-
15 (ELISA) were tested in group A and group B. Respectively at 4 w, 8 w and
12 w, plasma albumin, liver and kidney function, 24-hour urine protein quan-
titative, plasma concentrations of GDF-15 (ELISA) were tested in group B.
Results: Plasma level of GDF-15 in patients with primary nephrotic syndrome
was significantly higher than in healthy adults (P < 0.05). Plasma level of
GDF-15 in patients treated with glucocorticoid and tacrolimus treatment
was significantly lower than that before treatment (P < 0.05; Figure 1).
GDF-15 level was positively related with primary nephrotic syndrome
(r Z 0.624, P < 0.05).
Conclusion: GDF-15 may be an important pathogenic factor in primary
nephrotic syndrome, and may provide new targets for the treatment of
nephrotic syndrome.http://dx.doi.org/10.1016/j.hkjn.2015.09.020
